Skip to main content
. 2023 Aug 25;29(9):2216–2223. doi: 10.1038/s41591-023-02494-2

Extended Data Table 6.

Pharmacodynamic measurements of lipid parameters: percent change from baseline at day 113 and percent change from baseline compared to placebo for ANGPTL3, TG, VLDL-C, non-HDL-C, LDL-C, HDL-C, Apo CIII, total cholesterol, Apo B, Apo AI and Lp(a) in participants with hepatic steatosis receiving repeat doses of 200 mg of ARO-ANG3

graphic file with name 41591_2023_2494_Tab6_ESM.jpg